Your session is about to expire
← Back to Search
BBT-877 for Idiopathic Pulmonary Fibrosis
Study Summary
This trial will evaluate a potential new treatment for IPF with or without AF, to see if it's safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your emphysema is more severe than your fibrosis.I am not taking medications that could affect the study's results.Your lung function should be at least 45% of what is expected for someone of your age and size.Your lung function test shows that the amount of air you can breathe out quickly is normal compared to the total amount of air you can breathe out.Your lung function test result (DLCO) is at least 30% of what's expected for someone your age and size.You are currently smoking tobacco or using e-cigarettes.My lung condition hasn't improved in the last year.I have been on a stable dose of pirfenidone or nintedanib for at least 3 months, or I am not taking either.The doctor thinks you have less than a year or less than 2 and a half years to live.I am on medication for pulmonary hypertension.I have had a lung transplant or surgery to reduce lung volume.I have severe heart failure.I haven't had any major heart, lung, or other serious health issues in the last 6 months.You are not able to do the breathing test called spirometry as per the American Thoracic Society guidelines.My lung condition has worsened in the last 3 months.I am a man who does not plan to have more children or a woman aged 40 or older.My oxygen levels are stable with minimal extra oxygen needed.I can walk 150 meters or more without stopping.My condition is officially diagnosed as IPF by recognized guidelines.I've had a detailed lung scan within the last year or during screening for IPF diagnosis.I have a condition that weakens my immune system.
- Group 1: Placebo
- Group 2: BBT-877
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there still opportunity for enrollment in this clinical trial?
"The information accessible on clinicaltrials.gov reveals that this trial is actively searching for patients and has been since February 21st, 2023 with the last update being made a day earlier."
Has the FDA sanctioned BBT-877 for therapeutic applications?
"Data collected to date suggests that BBT-877 is relatively safe, so it was allocated a score of 2. This Phase 2 trial has only been effective at proving the drug's safety and not its efficacy."
What is the total sample size of this research experiment?
"Yes, the records hosted by clinicaltrials.gov verify that recruitment for this study is currently underway. It was first published on February 21st 2023 and has been amended as of February 20th 2023. The trial requires 120 participants from 2 different medical centres."
Who else is applying?
What portion of applicants met pre-screening criteria?
What site did they apply to?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger